Stay updated on Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the funding lapse notice and prior Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T05:33:01.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A government funding status banner was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T05:15:21.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page received minor UI and metadata updates, including showing the glossary, adding a QC status label, updating to revision v3.4.0, and capitalization adjustments to No FEAR Act text.
    Difference
    0.2%
    Check dated 2026-01-28T02:42:49.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no visible changes to the study details page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T00:35:46.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Added Minnesota under the Locations section and removed the Minnesota Locations entry. Page revision updated to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T08:09:56.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Revision from v3.3.1 to v3.3.2 appears to be a minor update to page formatting or documentation; no changes to study content, eligibility criteria, endpoints, or locations were changed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:33:10.000Z thumbnail image

Stay in the know with updates to Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab, Ixazomib, Dexamethasone in Relapsed Myeloma Clinical Trial page.